Latest News

IL-2 Effective in Metastatic Renal Cell Carcinoma (RCC) Patients with Favorable Histologies

IL-2 Effective in Metastatic Renal Cell Carcinoma (RCC) Patients with Favorable Histologies

Although the range of therapies for metastatic renal cell carcinoma (mRCC) is growing, managing the disease is still a challenge for clinicians.

Consider Febrile Neutropenia Risk When Administering Standard Treatment in Prostate Cancer

Consider Febrile Neutropenia Risk When Administering Standard Treatment in Prostate Cancer

Docetaxel can induce adverse events like febrile neutropenia in prostate cancer patients.

Docetaxel Plus Oxaliplatin with 5-Fluorouracil May Be Effective for Advanced Gastric Cancer

Docetaxel Plus Oxaliplatin with 5-Fluorouracil May Be Effective for Advanced Gastric Cancer

Docetaxel, oxaliplatin, and 5-fluorouracil (TEF) may be effective for the treatment of patients with advanced gastric cancer.

Imatinib Most Common Kinase Inhibitor (TKI) for First-Line Treatment of Chronic Myeloid Leukemia

Imatinib Most Common Kinase Inhibitor (TKI) for First-Line Treatment of Chronic Myeloid Leukemia

Imatinib was used more often than other tyrosine kinase inhibitors (TKIs) for the first-line treatment of chronic myeloid leukemia (CML).

Panobinostat Is Not Ready for U.S. Market According to the Oncologic Drugs Advisory Committee

Panobinostat Is Not Ready for U.S. Market According to the Oncologic Drugs Advisory Committee

The Oncologic Drugs Advisory Committee has voted against a recommendation for FDA approval of panobinostat for multiple myeloma.

Renal Cell Carcinoma More Advanced at Presentation in Younger Patients Than Those 21-30 Years Old

Renal Cell Carcinoma More Advanced at Presentation in Younger Patients Than Those 21-30 Years Old

Children and adolescents with renal cell carcinoma present with more advanced disease.

Melanoma Immunotherapy Slows Tumor Growth and Improves Survival in Mice

Melanoma Immunotherapy Slows Tumor Growth and Improves Survival in Mice

A new DNA-based cancer immunotherapy that targets melanoma has induced large immune response in animal models.

Tocilizumab Plus Standard of Care May Reduce Risk of Graft-Versus-Host-Disease After Stem-Cell Transplantation

Tocilizumab Plus Standard of Care May Reduce Risk of Graft-Versus-Host-Disease After Stem-Cell Transplantation

Addition of tocilizumab to standard graft-versus-host disease (GVHD) prophylaxis following allogenic stem-cell transplantation may be effective.

Hookah Smoke Increases Benzene Levels, Is No Safer than Tobacco Smoking

Hookah Smoke Increases Benzene Levels, Is No Safer than Tobacco Smoking

People who smoke hookah had a signficiantly increased amount of benzene and leukemia risk.

Subcutaneous Trastuzumab May Be as Safe and Effective as Intravenous Formulation

Subcutaneous Trastuzumab May Be as Safe and Effective as Intravenous Formulation

Researchers have found that the safety profile of subcutaneous trastuzumab was consistent with previous data from the phase 3 HannaH study.

Mastectomy Rates Rising Among Women with Breast Cancer Eligible for Lumpectomy

Mastectomy Rates Rising Among Women with Breast Cancer Eligible for Lumpectomy

Better breast reconstruction outcomes may be one reason behind the trend of rising mastectomy rates.

Genetic Diversity May Improve Melanoma Therapy Response

Genetic Diversity May Improve Melanoma Therapy Response

Whole-exome sequencing of melanoma tumor tissue reveals genetic basis for benefit from CTLA-4 blockade.

Figitumumab Not Safe or Effective for Advanced Non-Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC)

Figitumumab Not Safe or Effective for Advanced Non-Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC)

Figitumumab to erlotinib did not improve overall survival in patients with advanced, non-adenocarcinoma non-small cell lung cancer (NSCLC).

GALNT4 Expression as a Prognostic Indicator in Clear Cell Renal Cell Carcinoma

GALNT4 Expression as a Prognostic Indicator in Clear Cell Renal Cell Carcinoma

Researchers sought to identify the clinical meaning of GALNT4 expression in patients with clear cell renal cell carcinoma.

For BRAF-Mutated Colorectal Cancer, Encorafenib, Cetuximab, and Alpelisib May Be Effective

For BRAF-Mutated Colorectal Cancer, Encorafenib, Cetuximab, and Alpelisib May Be Effective

Cetuximab, encorafenib, and alpelisib, may be an effective treatment for patients with BRAF-mutated advanced colorectal cancer.

More News

Health Care Expenditure Slowed in US

Health sector prices explain much of difference between U.S. and other high-spending countries.

States Concerned About Higher-Than-Expected Medicaid Enrollment

Millions signing up for Medicaid to comply with federal health care law.

EHR Use More Than Doubles

Almost 80% of doctors in the United States have switched from paper to electronic health records.

Many Docs Order Unnecessary Medical Tests

Most physicians believe that doctors order too many medical tests, yet half admit to doing so themselves in response to a patient who insists, a new survey shows.

Reducing Six Risk Factors May Prevent 37 Million Deaths

Several modifiable risk factors can cut chronic disease deaths over the next 15 years.

Majority of Women Lack Accurate Knowledge of Their Own Breast Cancer Risk

Caucasian women overestimate their risk of breast cancer while African American and Hispanic women underestimate their risk, according to research presented at BCS 2013.

Survey Identifies Modifiable Barriers to Mammography Screening Among Rural US Women

A survey presented at BCS 2013 has found a number of factors that cause rural US women to avoid breast cancer screening.

Perioperative MRI of Uncertain Benefit for Women with DCIS

The benefit of perioperative MRI for women with ductal carcinoma in situ (DCIS) is "uncertain," found a study presented during BCS 2013.

Dr. Edith Perez's Recommended Abstracts at BCS 2013

ChemotherapyAdvisor.com Editorial Board member Dr. Edith Perez of the Mayo Clinic, Jacksonville, FL, recommends high impact abstracts at the Breast Cancer Symposium 2013.

Radiotherapy for DCIS Is Not Associated With Increased Cardiovascular Disease

Women who underwent radiation for ductal carcinoma in situ do not face an increased risk of cardiovascular disease, found a study presented at BCS 2013.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs